Navigation Links
Ovarian Cancer - Pipeline Review, H2 2016
Date:1/6/2017

LONDON, Jan. 5, 2017 /PRNewswire/ -- Ovarian Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer – Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.


Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Download the full report: https://www.reportbuyer.com/product/2458434/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ovarian-cancer---pipeline-review-h2-2016-300386827.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 ASCO Annual Meeting Shows Early Activity in Ovarian Cancer
2. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
3. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
4. Supreme Court Ruling Today Allows DNATraits to Offer Low Cost BRCA Breast and Ovarian Cancer Gene Testing in U.S.
5. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
6. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
7. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
8. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
9. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
10. CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer
11. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2020)... ... , ... The Sea Cucumber-derived triterpenoid glycoside Frondoside A, which has been extensively ... Sea Cucumber in a proprietary process to give SeaCare Dietary Supplement a ... time again: “You get what you pay for.” It is usually in reference to ...
(Date:5/16/2020)... ... 2020 , ... The private clinic, CLNQ has launched a coronavirus antibody ... test which is manufactured by Abbott has been CE certified and previously had FDA ... a finger-prick blood testing kit to be sent their home. The sample is ...
(Date:5/16/2020)... ... 16, 2020 , ... Mold needs oxygen, moisture, warmth and food to grow. ... Atascadero SERVPRO professionals advise that preventing water damage in the first place ... damage and mold gives people more information to help control moisture and water damage ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... 21, 2020 , ... A Safe Haven Foundation (ASHF) has been selected as ... COVID-19 Community Resilience Fund. The fund was created in March to help nonprofits with ... in service to vulnerable populations in hard-hit communities. , “We are humbled and ...
(Date:5/21/2020)... ... ... ESO , the leading data and software company serving emergency medical ... ESO Fire Service Index . The Index looks at key trends across fire departments ... and travel time, the most common property types visited and estimated property loss, as ...
(Date:5/21/2020)... ... May 21, 2020 , ... A new report from ... over 90 companies involved in the point of care test industry. Given the ... testing, COVID-19 has made point-of-care more important than in the past, according to the ...
(Date:5/16/2020)... ... May 15, 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D ... has always had in place. After being allowed to re-open during the current pandemic, they ... staff are as safe and comfortable as possible while going through their dental exams and ...
(Date:5/16/2020)... , ... May 16, 2020 , ... Dr. Tomasz ... early, this will prevent permanent arthritis from developing. This can keep the foot from ... further states “It is estimated that the people who develop flat feet and ...
Breaking Medicine News(10 mins):